Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706238 | 0.90 | KDM4E (0.53) | LMNAHPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31310732 | 0.89 | HPGD (0.45) | LMNAHPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31324002 | 0.84 | ALDH1A1 (0.47) | LMNAHPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL27743070 | 0.84 | LMNA (0.65) | LMNAHPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL27763674 | 0.82 | HPGD (0.69) | LMNAHPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3977275 | 0.82 | LMNA (0.63) | LMNAHPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL13799056 | 0.82 | LMNA (0.51) | LMNAHPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4980197 | 0.78 | LMNA (0.47) | LMNAHPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31310749 | 0.78 | HPGD (0.43) | LMNAHPGDALDH1A1KDM4EHSD17B10 | |
| SCHEMBL15146763 | 0.77 | MAPT (0.51) | LMNAALDH1A1KDM4ESMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569550-B2 | 14 and 15 membered ring compounds | GLAXO GROUP LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | CYP51A1, LSS, IL17A | LMNA 2615/4885HPGD 1267/4885ALDH1A1 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.